Zobrazeno 1 - 10
of 649
pro vyhledávání: '"Prior Therapy"'
Autor:
Anshu Srivastava, Nilay Nishith, Moinak Sen Sarma, Ujjal Poddar, Rakesh Pandey, Srinivas Srinidhi Vadlapudi
Publikováno v:
Pediatric Hematology Oncology Journal, Vol 6, Iss 4, Pp 186-189 (2021)
A ten-month-old infant presented with large hepatomegaly, hypertension and clinical tumour lysis syndrome (TLS). Computerized tomography of the abdomen and chest was suggestive of hepatoblastoma (HB) with lung metastasis. Serum alpha-fetoprotein was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a7af03228f70fa9c1840d11cd53be43
http://www.sciencedirect.com/science/article/pii/S2468124521002448
http://www.sciencedirect.com/science/article/pii/S2468124521002448
Publikováno v:
European Journal of Cancer. 159:56-59
Modern clinical cancer research increasingly relies on the visual communication of complex response and treatment sequencing data. Graphical representations used in oncology currently fail to provide adequate information on any prior treatment(s) res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff5ad5f1de2e5c4320f66c641800e403
https://doi.org/10.1016/j.ejca.2021.09.034
https://doi.org/10.1016/j.ejca.2021.09.034
Autor:
Erminia Massarelli, Min Hua Jen, Jennifer Kherani, Valentina Boni, Vivek Subbiah, Aaron C. Tan, Anna Minchom, Elizabeth Olek, Lori J. Wirth, Caroline E. McCoach, Bruce G. Robinson, Lisa M. Hess
Publikováno v:
Oncologist
Background LIBRETTO-001 is an ongoing, global, open-label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient-reported outcomes in patients with RET fusion–positive non-small cell lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a125a02252c31f143792561677be1457
https://doi.org/10.1002/onco.13976
https://doi.org/10.1002/onco.13976
Autor:
Orlando M. Gutiérrez
Publikováno v:
Kidney International Reports
Iron deficiency is common in individuals with chronic kidney disease and plays a major role in the development of anemia. Oral and intravenous iron agents are both available to replete iron in patients with chronic kidney disease diagnosed with iron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a6eb75d07ee0b4c28550e503daad1fc
https://doi.org/10.1016/j.ekir.2021.05.020
https://doi.org/10.1016/j.ekir.2021.05.020
Publikováno v:
Leukemia & Lymphoma. 63:162-169
Treatment-free remission is achievable in approximately half of patients with chronic myeloid leukemia who attain a sustained, deep molecular response with tyrosine-kinase inhibitor (TKI) therapy. We aimed to identify potential predictors of future a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca90f5f10bb4a27ae093667c3838fc78
https://doi.org/10.1080/10428194.2021.1961234
https://doi.org/10.1080/10428194.2021.1961234
Autor:
Hope S. Rugo, Stephen Chia, Wei-Chun Hsu, Juan Pablo Zarate, Hemanth Kanakamedala, David Chandiwana, Chu-Ling Yu, Jinhee Park, Antonia Ridolfi, Stuart J. Turner
Publikováno v:
The Oncologist
Background The BYLieve trial (NCT03056755) confirmed efficacy and safety of alpelisib with fulvestrant for hormone receptor–positive (HR+), human epidermal growth factor receptor‐2–negative (HER2−), PIK3CA‐mutated advanced breast cancer (AB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2cb8cbf42e6cfbe7074f0e9f4f106b9
http://europepmc.org/articles/PMC8265362
http://europepmc.org/articles/PMC8265362
Autor:
Zaina T. Al-Salama
Publikováno v:
Drugs. 81:849-856
Encorafenib (Braftovi®) is an oral small molecule BRAF inhibitor used in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, who have received prior systemic therapy. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ad9321fc6762547e32ce8de5a8fcdb4
https://doi.org/10.1007/s40265-021-01501-5
https://doi.org/10.1007/s40265-021-01501-5
Autor:
Kelsey Poorman, John Y. Hu, Sushma Jonna, Stephen V. Liu, Xinyu von Buttlar, Ari M. Vanderwalde, Jorge Nieva, Michelle Saul
Publikováno v:
Transl Lung Cancer Res
Background Higher tumor mutation burden (TMB) in advanced non-small cell lung cancer (NSCLC) is associated with superior outcomes with checkpoint inhibitor therapy. Tissue samples subject to TMB analysis may be acquired after DNA-damaging therapies s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccd685da253d4a305e1ff25f9cbbcfe7
https://doi.org/10.21037/tlcr-20-1076
https://doi.org/10.21037/tlcr-20-1076
Autor:
Anthony Markham
Publikováno v:
Drugs. 81:291-296
Naxitamab (DANYELZA®, naxitamab-gqgk) is a humanised (IgG1) anti-GD2 (hu3F8) monoclonal antibody was developed by the Memorial Sloan Kettering Cancer Center (with commercial rights licenced to Y-mAbs therapeutics Inc.) for the treatment of neuroblas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c971f7740c70b4008f9aaca829aaf318
https://doi.org/10.1007/s40265-021-01467-4
https://doi.org/10.1007/s40265-021-01467-4
Autor:
Adonis Hijaz, Kirtishri Mishra, Amr Mahran, Anood Alfahmy, J. Stephen Jones, Adam C. Calaway, Austin Fernstrum, Wade Muncey, Thomas J. Polascik, Ahmed Elshafei, Molly E. DeWitt-Foy
Publikováno v:
Prostate Cancer and Prostatic Diseases. 24:507-513
BACKGROUND To assess whether prior interventional treatment for benign prostatic hyperplasia (BPH) influences oncologic or functional outcomes following primary whole-gland prostate cryoablation. METHODS Among 3831 men with prostate cancer who underw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a89309dc1ae7e6013acc290fd6fc2cdf
https://doi.org/10.1038/s41391-020-00306-z
https://doi.org/10.1038/s41391-020-00306-z